Compare WBI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBI | XNCR |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.9M |
| IPO Year | N/A | 2013 |
| Metric | WBI | XNCR |
|---|---|---|
| Price | $26.97 | $11.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $28.00 | $22.89 |
| AVG Volume (30 Days) | ★ 1.1M | 741.6K |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $67.95 | N/A |
| Revenue Next Year | $16.92 | $11.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $18.64 | $6.92 |
| 52 Week High | $27.57 | $18.69 |
| Indicator | WBI | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.84 | 49.09 |
| Support Level | $23.22 | $10.92 |
| Resistance Level | $26.85 | $12.87 |
| Average True Range (ATR) | 1.38 | 0.70 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 95.28 | 56.90 |
WaterBridge Infrastructure LLC is integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates the largest produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling and handling produced water. It also operate two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment and handling of produced water is crucial to oil and natural gas production.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.